Konstantin Dobrenkov

1.1k total citations
28 papers, 829 citations indexed

About

Konstantin Dobrenkov is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Konstantin Dobrenkov has authored 28 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Konstantin Dobrenkov's work include Cancer Immunotherapy and Biomarkers (10 papers), Neuroblastoma Research and Treatments (7 papers) and Immunotherapy and Immune Responses (7 papers). Konstantin Dobrenkov is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Neuroblastoma Research and Treatments (7 papers) and Immunotherapy and Immune Responses (7 papers). Konstantin Dobrenkov collaborates with scholars based in United States, Israel and Australia. Konstantin Dobrenkov's co-authors include Nai‐Kong V. Cheung, Vladimir Ponomarev, Michel Sadelain, Glenn Heller, Alex H. Chang, Renier J. Brentjens, Matthias T. Stephan, Irina Ostrovnaya, Jessie Gu and Irene Y. Cheung and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Konstantin Dobrenkov

27 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Konstantin Dobrenkov United States 15 559 363 235 190 131 28 829
Connie Lee Batlevi United States 17 763 1.4× 198 0.5× 270 1.1× 138 0.7× 91 0.7× 83 1.1k
Skyler P. Rietberg United States 7 779 1.4× 309 0.9× 324 1.4× 184 1.0× 297 2.3× 9 1.0k
Parisa Malekzadeh United States 7 651 1.2× 377 1.0× 196 0.8× 101 0.5× 150 1.1× 14 795
Christopher DeRenzo United States 12 541 1.0× 249 0.7× 172 0.7× 122 0.6× 172 1.3× 24 638
Katrin Töpfer Germany 11 655 1.2× 536 1.5× 246 1.0× 141 0.7× 105 0.8× 12 896
Bianca Altvater Germany 24 993 1.8× 736 2.0× 355 1.5× 201 1.1× 183 1.4× 44 1.4k
Sareetha Kailayangiri Germany 16 718 1.3× 524 1.4× 272 1.2× 122 0.6× 124 0.9× 29 1.0k
Slava Stamova Germany 13 617 1.1× 388 1.1× 163 0.7× 91 0.5× 146 1.1× 22 752
Qiangzhong Ma United States 14 884 1.6× 503 1.4× 261 1.1× 274 1.4× 257 2.0× 18 1.1k
Kathleen Gallagher United States 12 633 1.1× 195 0.5× 196 0.8× 151 0.8× 212 1.6× 32 837

Countries citing papers authored by Konstantin Dobrenkov

Since Specialization
Citations

This map shows the geographic impact of Konstantin Dobrenkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantin Dobrenkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantin Dobrenkov more than expected).

Fields of papers citing papers by Konstantin Dobrenkov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Konstantin Dobrenkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantin Dobrenkov. The network helps show where Konstantin Dobrenkov may publish in the future.

Co-authorship network of co-authors of Konstantin Dobrenkov

This figure shows the co-authorship network connecting the top 25 collaborators of Konstantin Dobrenkov. A scholar is included among the top collaborators of Konstantin Dobrenkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantin Dobrenkov. Konstantin Dobrenkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rha, Sun Young, Wilson H. Miller, Maria J. de Miguel, et al.. (2023). Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.. Journal of Clinical Oncology. 41(4_suppl). 394–394. 7 indexed citations
2.
Moreno, Víctor, Emiliano Calvo, Mark R. Middleton, et al.. (2022). Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. Cancer Immunology Immunotherapy. 71(12). 2985–2998. 19 indexed citations
3.
Moroz, Maxim A., Juan Zurita, Konstantin Dobrenkov, et al.. (2021). Introducing a new reporter gene, membrane-anchored Cypridina luciferase, for multiplex bioluminescence imaging. Molecular Therapy — Oncolytics. 21. 15–22. 10 indexed citations
4.
Papadopoulos, Kyriakos P., Karen A. Autio, Talia Golan, et al.. (2020). Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clinical Cancer Research. 27(7). 1904–1911. 46 indexed citations
5.
6.
7.
Middleton, Mark R., Martin Wermke, Emílio Calvo, et al.. (2018). Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors. Annals of Oncology. 29. viii712–viii712. 20 indexed citations
8.
9.
Hoseini, Sayed Shahabuddin, Konstantin Dobrenkov, Dmitry Pankov, Xiaoliang L. Xu, & Nai‐Kong V. Cheung. (2017). Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. OncoImmunology. 6(6). e1320625–e1320625. 31 indexed citations
10.
Dobrenkov, Konstantin, Irina Ostrovnaya, Irene Y. Cheung, Yi Feng, & Nai‐Kong V. Cheung. (2016). GD2/GD3 expression: Companion diagnostic for ganglioside-targeted immunotherapy against pediatric solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 10567–10567. 2 indexed citations
11.
Dobrenkov, Konstantin, Irina Ostrovnaya, Jessie Gu, Irene Y. Cheung, & Nai‐Kong V. Cheung. (2016). Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatric Blood & Cancer. 63(10). 1780–1785. 104 indexed citations
12.
Kachanov, D. Yu., et al.. (2014). Malignant rhabdoid tumor of the liver presented with initial tumor rupture. Cancer Genetics. 207(9). 412–414. 5 indexed citations
13.
Dobrenkov, Konstantin & Nai‐Kong V. Cheung. (2014). GD2-Targeted Immunotherapy and Radioimmunotherapy. Seminars in Oncology. 41(5). 589–612. 66 indexed citations
14.
Waseem, Muhammad, et al.. (2012). Paroxysmal Neuropathic Pain in an Adolescent Female With Syringomyelia. Pediatric Emergency Care. 28(5). 472–474. 2 indexed citations
15.
Benezra, Miriam, Elizabeth Phillips, Derya Tilki, et al.. (2012). Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent. Leukemia. 26(8). 1771–1778. 16 indexed citations
16.
Zurita, Juan, Konstantin Dobrenkov, Larissa Shenker, et al.. (2010). A New Pyrimidine-Specific Reporter Gene: A Mutated Human Deoxycytidine Kinase Suitable for PET During Treatment with Acycloguanosine-Based Cytotoxic Drugs. Journal of Nuclear Medicine. 51(9). 1395–1403. 51 indexed citations
17.
Dobrenkov, Konstantin, Malgorzata Olszewska, Larissa Shenker, et al.. (2009). PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers. European Journal of Nuclear Medicine and Molecular Imaging. 36(8). 1273–1282. 12 indexed citations
18.
Dobrenkov, Konstantin, Malgorzata Olszewska, Larissa Shenker, et al.. (2008). Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging. Journal of Nuclear Medicine. 49(7). 1162–1170. 67 indexed citations
19.
Stephan, Matthias T., Vladimir Ponomarev, Renier J. Brentjens, et al.. (2007). T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 13(12). 1440–1449. 237 indexed citations
20.
Kimura, Hideki, et al.. (2005). Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.. PubMed. 25(1A). 85–94. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Connie Lee Batlevi Breakdown of academic impact, for papers by Skyler P. Rietberg Breakdown of academic impact, for papers by Parisa Malekzadeh Breakdown of academic impact, for papers by Christopher DeRenzo Breakdown of academic impact, for papers by Katrin Töpfer Breakdown of academic impact, for papers by Bianca Altvater Breakdown of academic impact, for papers by Sareetha Kailayangiri Breakdown of academic impact, for papers by Slava Stamova Breakdown of academic impact, for papers by Qiangzhong Ma Breakdown of academic impact, for papers by Kathleen Gallagher
Rankless by CCL
2026